Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is 7.94%. On last trading day company shares ended up $8.49. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -2.43%. On 1 July, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) declared long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Vital Therapies, Inc. (NASDAQ:VTL) shares moved up 6.37% in last trading session and ended the day at $26.71. VTL return on assets is -60.00%. Vital Therapies, Inc. (NASDAQ:VTL) quarterly performance is -4.13%. Zacks upgraded shares of Vital Therapies Inc. (NYSE:VTL) from a hold rating to a buy rating in a report released on Tuesday.
On 14 July, Emmis Communications Corp. (NASDAQ:EMMS) shares fell -3.10% and was closed at $1.25. EMMS EPS growth in last 5 year was 8.20%. Emmis Communications Corp. (NASDAQ:EMMS) year to date (YTD) performance is -33.16%. On 9 July, Emmis Communications Corp. (NASDAQ:EMMS) reported fiscal first quarter net income of $1.5 million, compared to $956,000 the same period the previous year. The company says radio revenues dipped more than 5 percent.
Synalloy Corporation (NASDAQ:SYNL) ended the last trading day at $13.38. Company weekly volatility is calculated as 3.28% and price to cash ratio as 584.04. Synalloy Corporation (NASDAQ:SYNL) showed a weekly performance of -1.25%. Synalloy Corporation (NASDAQ:SYNL) announced that effective immediately, Dennis M. Loughran has joined the company as Senior Vice President and Chief Financial Officer.
Pfizer Inc. (NYSE:PFE) shares increased 0.75% in last trading session and ended the day at $35.08. PFE Gross Margin is 81.00% and its return on assets is 6.80%. Pfizer Inc. (NYSE:PFE) quarterly performance is 0.97%. Pfizer Inc. (NYSE:PFE) has offered concessions in a bid to win European Union regulatory approval for its $15 billion takeover of U.S. rival Hospira (HSP.N), the European Commission said on Tuesday. The EU competition authority did not provide details of Pfizer’s proposal in line with its policy. It extended the deadline for its decision to Aug. 4 from July 20 to examine the concessions.